Elanco Animal Health (NYSE:ELAN) Upgraded by KeyCorp to Strong-Buy Rating

KeyCorp upgraded shares of Elanco Animal Health (NYSE:ELAN) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Piper Sandler raised their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, August 11th. Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Wednesday. Finally, Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.56.

Elanco Animal Health Stock Down 1.0%

Shares of ELAN stock opened at $21.24 on Thursday. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $23.09. The stock’s fifty day moving average price is $20.80 and its 200 day moving average price is $16.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The company has a market cap of $10.55 billion, a price-to-earnings ratio of 353.98, a price-to-earnings-growth ratio of 2.92 and a beta of 1.71.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm’s revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently added to or reduced their stakes in the business. Comerica Bank grew its holdings in Elanco Animal Health by 46.4% in the first quarter. Comerica Bank now owns 49,680 shares of the company’s stock valued at $522,000 after purchasing an additional 15,754 shares during the period. Equitable Trust Co. raised its stake in shares of Elanco Animal Health by 65.5% during the 2nd quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock worth $3,543,000 after buying an additional 98,172 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Elanco Animal Health by 14.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 13,404 shares of the company’s stock valued at $141,000 after buying an additional 1,641 shares in the last quarter. US Bancorp DE grew its stake in Elanco Animal Health by 18.7% in the 1st quarter. US Bancorp DE now owns 14,906 shares of the company’s stock valued at $157,000 after acquiring an additional 2,346 shares during the period. Finally, Callan Family Office LLC grew its stake in Elanco Animal Health by 239.0% in the 2nd quarter. Callan Family Office LLC now owns 166,198 shares of the company’s stock valued at $2,373,000 after acquiring an additional 117,174 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.